Skip to main content
×
×
Home

Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study

  • S. Oehrberg (a1), P. E. Christiansen (a2), K. Behnke (a3), A. L. Borup (a4), B. Severin (a5), J. Soegaard (a6), H. Calberg (a7), R. Judge (a8), J. K. Ohrstrom (a9) and P. M. Manniche (a8)...
Abstract
Background

This study compared the efficacy and tolerability of paroxetine with placebo in the treatment of panic disorder.

Method

After three weeks of placebo, patients received 12 weeks of treatment with paroxetine (20, 40, or 60 mg) or placebo, and finally two weeks of placebo. Dosages were adjusted according to efficacy and tolerability. Standardised cognitive therapy was given to all patients. The primary measure of outcome was reduction in the number of panic attacks.

Results

Analysis of the results showed statistically significant differences in favour of paroxetine between the two treatment groups in two out of the three primary measures of outcome, i.e. 50% reduction in total number of panic attacks and number of panic attacks reduced to one or zero over the study period. For the third measure of outcome, the mean change in the total number of attacks from baseline, there was a positive trend in favour of paroxetine. The results of the primary measures of outcome were strongly supported by the results of the secondary efficacy measures of outcome. In addition, paroxetine, at all doses, was very well tolerated.

Conclusion

Paroxetine plus cognitive therapy was significantly more effective than placebo plus cognitive therapy in the treatment of panic disorder.

Copyright
Corresponding author
Dr R. Judge, CNS Therapeutic Unit, SmithKline Beecham Pharmaceuticals, New Frontier Science Park South, Third Avenue, Harlow, Essex CM19 5AG
References
Hide All
American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). Washington, DC: APA.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington, DC: APA.
Beck, A. T., Sokol, L., Clark, D. A., et al (1992) A crossover study of focussed cognitive therapy for panic disorder. American Journal of Psychiatry, 149, 6.
Black, D. W., Wesner, R., Bowers, W., et al (1993) A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Archives of General Psychiatry, 50, 4450.
Chambless, D. L. & Gillis, M. M. (1993) Cognitive therapy of anxiety disorders. Journal of Consulting and Clinical Psychology, 61, 248260.
den Boer, J. A. (1988) Serotonergic Mechanisms in Anxiety Disorder. Cip-Gegevens Koninklijke Bibiotheek, Den Haag.
Dunbar, G. C. (1989) An interim overview of safety and tolerability of paroxetine. Acta Psychiatrica Scandinavica, 80 (suppl. 350), 135137.
Feighner, J. P. & Boyer, W. F. (1989) Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatrica Scandinavica, 80 (suppl.), 125129.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration.
Hamilton, M. (1969) Diagnosis and rating of anxiety. British Journal of Psychiatry, 3, 7679.
Hawton, K., Salkowski, P., Kirk, J., et al (1989) Cognitive Behaviour Therapy for Psychiatric Problems. Oxford: Oxford University Press.
Humble, M. & Wistedt, B. (1992) Serotonin, panic disorder and agoraphobia: short term and long term efficacy of citalopram in panic disorders. International Clinical Psychopharmacology, 6 (suppl. 5), 2139.
Kahn, R. S. & van Praag, H. M. (1992) Panic disorder: a biological perspective. European Neuropsychopharmacology, 2, 120.
Maier, W., Roth, M., Argyle, N., et al (1991) Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder. European Archives of Psychiatry and Clinical Neuroscience, 241, 151158.
Rosenberg, N. K., Andersch, S., Kullingsjo, H., et al (1991) Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. Acta Psychiatrica Scandinavica (suppl. 365), 1827.
Salzman, C. (1993) Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. Journal of Psychiatric Research, 27 (suppl. 1), 97100.
Schneier, F. R., Liebowitz, M. R., Davies, S. O., et al (1990) Fluoxetine in panic disorder. Journal of Clinical Psychopharmacology, 10, 119121.
Uhde, T. W., Boulenger, J. P., Roy Byrne, P. P., et al (1985) Longitudinal course of panic disorder: clinical and biological considerations. Progress in Neuropsychopharmacology and Biological Psychiatry, 9, 3951.
Wittchen, H. U. & Essau, C. A. (1993) Epidemiology of panic disorder: progress and unresolved issues. Journal of Psychiatric Research, 27 (suppl.), 4768.
Zung, W. W. K. (1971) A rating instrument for anxiety disorders. Psychosomatics, 12, 371379.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study

  • S. Oehrberg (a1), P. E. Christiansen (a2), K. Behnke (a3), A. L. Borup (a4), B. Severin (a5), J. Soegaard (a6), H. Calberg (a7), R. Judge (a8), J. K. Ohrstrom (a9) and P. M. Manniche (a8)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *